Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment with RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Next Previous
Trial Profile

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment with RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apabetalone (Primary) ; Atorvastatin; Rosuvastatin
  • Indications Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Coronary artery disease; Ischaemic pain; Myocardial infarction; Myocardial ischaemia; Stroke; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms BETonMACE
  • Sponsors Resverlogix Corporation

Most Recent Events

  • 22 Aug 2022 Results published in Resverlogix Corporation Media Release.
  • 22 Aug 2022 According to a Resverlogix Corporation media release, post-hoc analysis were presented in in the American Journal of Preventive Cardiology.
  • 17 Mar 2022 According to a Resverlogix Corporation media release, apabetalone received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) in Feb 2020 following the ground-breaking findings from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top